Literature DB >> 18445818

A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

Daniel F Hayes, Vered Stearns, James Rae, David Flockhart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18445818      PMCID： PMC2766275          DOI： 10.1093/jnci/djn127

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  43 in total

1.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Authors:  Silvana Borges; Zeruesenay Desta; Lang Li; Todd C Skaar; Bryan A Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D Michele Nikoloff; Lin Wu; Grant Hillman; Daniel F Hayes; Vered Stearns; David A Flockhart
Journal:  Clin Pharmacol Ther       Date:  2006-07       Impact factor: 6.875

Review 2.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Authors:  D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

Review 3.  Tamoxifen in the treatment of breast cancer.

Authors:  C K Osborne
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

4.  Estrogen receptors in hormone-dependent breast cancers.

Authors:  E V Jensen
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

5.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

Authors:  C L Loprinzi; J W Kugler; J A Sloan; J A Mailliard; B I LaVasseur; D L Barton; P J Novotny; S R Dakhil; K Rodger; T A Rummans; B J Christensen
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

6.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Authors:  Yan Jin; Zeruesenay Desta; Vered Stearns; Bryan Ward; Herbert Ho; Kyung-Hoon Lee; Todd Skaar; Anna Maria Storniolo; Lang Li; Adjei Araba; Rebecca Blanchard; Anne Nguyen; Lynda Ullmer; Jill Hayden; Suzanne Lemler; Richard M Weinshilboum; James M Rae; Daniel F Hayes; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2005-01-05       Impact factor: 13.506

7.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Authors:  A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

8.  Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites.

Authors:  A E Wakeling; S R Slater
Journal:  Cancer Treat Rep       Date:  1980 Jun-Jul

Review 9.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

10.  Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis.

Authors:  J N Ingle; D I Twito; D J Schaid; S A Cullinan; J E Krook; J A Mailliard; L K Tschetter; H J Long; J G Gerstner; H E Windschitl
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860
View more
  13 in total

1.  Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.

Authors:  Thomas P Ahern; Lindsay J Collin; James W Baurley; Anders Kjærsgaard; Rebecca Nash; Maret L Maliniak; Per Damkier; Michael E Zwick; R Benjamin Isett; Peer M Christiansen; Bent Ejlertsen; Kristina L Lauridsen; Kristina B Christensen; Rebecca A Silliman; Henrik Toft Sørensen; Trine Tramm; Stephen Hamilton-Dutoit; Timothy L Lash; Deirdre Cronin-Fenton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-13       Impact factor: 4.254

Review 2.  Expectations, validity, and reality in pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  J Clin Epidemiol       Date:  2009-12-07       Impact factor: 6.437

Review 3.  Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.

Authors:  Richard R Love
Journal:  Oncology (Williston Park)       Date:  2010-04-15       Impact factor: 2.990

Review 4.  Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.

Authors:  N Lynn Henry; Vered Stearns; David A Flockhart; Daniel F Hayes; Michelle Riba
Journal:  Am J Psychiatry       Date:  2008-10       Impact factor: 18.112

5.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

Authors:  Jean E Abraham; Mel J Maranian; Kristy E Driver; Radka Platte; Bolot Kalmyrzaev; Caroline Baynes; Craig Luccarini; Mitul Shah; Susan Ingle; David Greenberg; Helena M Earl; Alison M Dunning; Paul D P Pharoah; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

6.  Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.

Authors:  Alison Fohner; LeeAnna I Muzquiz; Melissa A Austin; Andrea Gaedigk; Adam Gordon; Timothy Thornton; Mark J Rieder; Mark A Pershouse; Elizabeth A Putnam; Kevin Howlett; Patrick Beatty; Kenneth E Thummel; Erica L Woodahl
Journal:  Pharmacogenet Genomics       Date:  2013-08       Impact factor: 2.089

Review 7.  Genotype-guided tamoxifen therapy: time to pause for reflection?

Authors:  Timothy L Lash; Ernst A Lien; Henrik Toft Sørensen; Stephen Hamilton-Dutoit
Journal:  Lancet Oncol       Date:  2009-08       Impact factor: 41.316

Review 8.  Clinically available pharmacogenomics tests.

Authors:  D A Flockhart; T Skaar; D S Berlin; T E Klein; A T Nguyen
Journal:  Clin Pharmacol Ther       Date:  2009-04-15       Impact factor: 6.875

9.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Authors:  James M Rae; Suzy Drury; Daniel F Hayes; Vered Stearns; Jacklyn N Thibert; Ben P Haynes; Janine Salter; Ivana Sestak; Jack Cuzick; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

10.  Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.

Authors:  Per Eystein Lønning
Journal:  Breast Cancer Res       Date:  2008-12-18       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.